FMP
enVVeno Medical Corporation
HJLI
NASDAQ
Inactive Equity
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.
10.38 USD
-0.21000004 (-2.02%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
443.89M
485.69M
557.42M
623.94M
724.14M
818.6M
925.38M
1.05B
1.18B
1.34B
-
9.42
14.77
11.93
16.06
13.04
13.04
13.04
13.04
141.94M
228.44M
259.48M
292.14M
-
282.22M
319.04M
360.65M
407.7M
460.88M
31.98
47.03
46.55
46.82
-
34.48
34.48
34.48
34.48
123.51M
208.4M
237.43M
269.95M
-21.68M
251.47M
284.27M
321.36M
363.28M
410.66M
27.82
42.91
42.59
43.27
-2.99
30.72
30.72
30.72
30.72
18.42M
20.04M
22.05M
22.19M
21.68M
30.75M
34.76M
39.3M
44.42M
50.22M
4.15
4.13
3.96
3.56
2.99
3.76
3.76
3.76
3.76
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)